Latest News for: ar 9

Edit

Statement of Changes in Beneficial Ownership (Form 4) (ARS Pharmaceuticals Inc)

Public Technologies 05 Dec 2024
) Ownership Submission FORM 4. Check this box if no longer subject to Section 16 ... See Instruction 1(b) ... 0.5 ... 2 ... ARS Pharmaceuticals, Inc ... C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120 3 ... C/O ARS PHARMACEUTICALS, INC ... ARS Pharmaceuticals Inc.
Edit

Over a lakh positions vacant in CAPFs and AR: Government

Deccan Herald 04 Dec 2024
<p>New Delhi. Over one lakh positions are vacant in <a href= .
Edit

zSpace Expands Workforce Training Applications on Headset-Free AR/VR Laptops at ACTE CareerTech VISION

Nasdaq Globe Newswire 04 Dec 2024
04, 2024 (GLOBE NEWSWIRE) -- zSpace, Inc., a leading innovator in augmented and virtual reality ...
Edit

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to ...

Nasdaq Globe Newswire 04 Dec 2024
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy� (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis ... .
Edit

zSpace Unveils Next-Generation Inspire 2 Series: Enhanced AR/VR Learning with Improved Performance and Portability

Nasdaq Globe Newswire 04 Dec 2024
... augmented and virtual reality (AR/VR) technology in education with a powerful, lightweight, and efficient design.
Edit

These Xreal AR glasses let you experience spatial computing for a fraction of the cost ...

ZDNet 04 Dec 2024
Xreal continues to push the limits of the smart glasses form factor, and its latest innovations are available now in the Xreal One Series ... .
Edit

Xreal One Series AR glasses offer leap forward with X1 custom coprocessor

Venture Beat 04 Dec 2024
Xreal unveiled a step change for its newest augmented reality (AR) glasses, Xreal One Series, that the company believes is the biggest leap forward in AR tech to date.Read More ....

Most Viewed

×